Across TCGA pan-cancer cohorts, GCSAM Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GCSAM data layer compared with 27 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher GCSAM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GCSAM expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.
SKCM and BLCA are the cancer types where GCSAM Mutation most reproducibly stratifies survival.